BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $29.00 at Cantor Fitzgerald

Posted by Stanley Muller on Jun 30th, 2026

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its price target boosted by equities researchers at Cantor Fitzgerald from $27.00 to $29.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 203.66% from the company’s current price.

A number of other analysts have also commented on the company. Wedbush cut their price target on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Needham & Company LLC dropped their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Citizens Jmp raised their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $21.00.

View Our Latest Report on BCRX

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $9.55 on Tuesday. The business’s 50-day simple moving average is $8.90 and its 200-day simple moving average is $8.27. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $10.94. The stock has a market capitalization of $2.43 billion, a PE ratio of -5.37 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The company had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. During the same quarter last year, the business posted $0.20 earnings per share. The business’s quarterly revenue was up 7.5% on a year-over-year basis. On average, research analysts expect that BioCryst Pharmaceuticals will post -2.66 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC raised its stake in BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 3,267 shares during the period. Focus Partners Wealth bought a new stake in BioCryst Pharmaceuticals in the 3rd quarter valued at $77,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in BioCryst Pharmaceuticals by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 2,115 shares during the last quarter. Hilltop Holdings Inc. bought a new position in BioCryst Pharmaceuticals during the first quarter worth $98,000. Finally, Envestnet Portfolio Solutions Inc. bought a new position in BioCryst Pharmaceuticals during the fourth quarter worth $81,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

(Get Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.